CA2474894A1 - Desaturase genes, enzymes encoded thereby, and uses thereof - Google Patents

Desaturase genes, enzymes encoded thereby, and uses thereof Download PDF

Info

Publication number
CA2474894A1
CA2474894A1 CA002474894A CA2474894A CA2474894A1 CA 2474894 A1 CA2474894 A1 CA 2474894A1 CA 002474894 A CA002474894 A CA 002474894A CA 2474894 A CA2474894 A CA 2474894A CA 2474894 A1 CA2474894 A1 CA 2474894A1
Authority
CA
Canada
Prior art keywords
acid
desaturase
fatty acid
polyunsaturated fatty
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002474894A
Other languages
French (fr)
Other versions
CA2474894C (en
Inventor
Pradip Mukerji
Suzette L. Pereira
Yung-Sheng Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Pradip Mukerji
Suzette L. Pereira
Yung-Sheng Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27658343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2474894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories, Pradip Mukerji, Suzette L. Pereira, Yung-Sheng Huang filed Critical Abbott Laboratories
Priority to CA2714295A priority Critical patent/CA2714295C/en
Publication of CA2474894A1 publication Critical patent/CA2474894A1/en
Application granted granted Critical
Publication of CA2474894C publication Critical patent/CA2474894C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6431—Linoleic acids [18:2[n-6]]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Abstract

Disclosed are isolated polynucleotides encoding an omega-3 desaturase and a delta-12 desaturase, the enzymes encoded by the isolated polynucleotides, vectors containing the isolated polynucleotides, transgenic hosts that contain the isolated polynucleotides that express the enzymes encoded thereby, methods for producing the desaturase enzymes, and method of using the enzymes to make polyunsaturated fatty acids. The isolated polynucleotides are derived from a fungus, Saprolegnia diclina (ATCC 56851). In particular, omega-3-desaturase may be utilized, for example, in the conversion of arachidonic acid (AA) to eicosapentaenoic acid (EPA). Delta-12 desaturase may be used, for example, in the conversion of oleic acid (OA) to linoleic (LA). EPA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Claims (39)

1. An isolated nucleotide acid sequence or fragment thereof comprising or complementary to a nucleotide sequence encoding a polypeptide having desaturase activity, wherein the amino acid sequence of said polypeptide has at least 50% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:26 and SEQ ID NO:42.
2. An isolated nucleotide sequence or fragment thereof comprising or complementary to at least 50% of the nucleotide sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:41.
3. The isolated nucleotide sequence of claim 2, wherein said sequence is selected from the group consisting of SEQ ID
NO:25 and SEQ ID NO:41.
4. The isolated nucleotide sequence of claim 2 or 3, wherein said sequence encodes a functionally active desaturase which utilizes a polyunsaturated fatty acid as a substrate.
5. The isolated nucleotide sequence of claim 1 or 2, wherein said sequence is derived from Saprolegnia diclina.
6. A purified polypeptide encoded by said isolated nucleotide sequence of claim 1 or 2.
7. A purified polypeptide that desaturates a polyunsaturated tatty acid substrate at an omega-3 carbon of said substrate and has at least 50% amino acid identity to an amino acid sequence comprising SEQ ID NO: 26.
8. The purified polypeptide of claim 7, wherein said polypeptide desaturates a fatty acid substrate having 20 carbon atoms.
9. A purified polypeptide that desaturates a polyunsaturated fatty acid substrate at a delta-12 carbon of said substrate and has at least 50% amino acid identity to SEQ ID NO:
42.
10. The purified polypeptide of claim 9, wherein said polypeptide desaturates a fatty acid substrate having 18 carbon atoms.
11. A method of producing a desaturase comprising the steps of:
(a) isolating a nucleotide sequence comprising or complementary to ut least 50% of the nucleotide sequence selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO: 41;
(b) constructing a vector comprising said isolated nucleotide sequence of step (a); and (c) introducing said vector of step (b) into a host cell for a time and under conditions sufficient for expression of a desaturase encoded by said isolated nucleotide sequence of step (a).
12. A vector comprising: 1) an isolated nucleotide sequence corresponding to or complementary to at least 50% of the nucleotide sequence selected from the group consisting of SEQ ID
NO: 25 and SEQ ID NO: 41, operably linked to b) a regulatory sequence.
13. A host cell comprising said vector of claim 12.
14. The host cell of claim 13, wherein said host cell is a eukaryotic cell selected from the group consisting of a mammalian cell, an insect cell, a plant cell and a fungal cell.
15. The host cell of claim 14, wherein expression of said isolated nucleotide sequence of said vector results in said host cell producing a polyunsaturated fatty acid that is not produced in a wild-type of said host cell.
16. A plant cell, plant, or plant tissue comprising said vector of claim 12, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid by said plant cell, plant or plant tissue.
17. The plant cell, plant, or plant tissue of claim 16, wherein said vector induces the production of a polyunsaturated fatty acid selected from the group consisting of linoleic acid, eicosatetraenoic acid and eicosapentaenoic acid.
18. A transgenic plant comprising said vector of claim 12, wherein expression of said nucleotide sequence of said vector results in production of a polyunsaturated fatty acid in seeds of said transgenic plant.
19. One or more plant oils or acids expressed by said plant cell, plant or plant tissue of claim 16.
20. A method for producing a polyunsaturated fatty acid comprising the steps of:
(a) isolating a nucleotide sequence comprising or complementary to at least 50% of the nucleotide sequence selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO: 41;
(b) constructing a vector comprising said isolated nucleotide sequence of step (a);
(c) transforming the vector of step (b) into a host cell for a time and under conditions sufficient for expression of a desaturase encoded by said isolated nucleotide sequence of step (a); and (d) exposing said expressed desaturase selected from the group consisting of an omega-3-desaturase and a delta 12-desaturase, to a fatty acid substrate, whereby said substrate is catalytically converted by said desaturase into a desired polyunsaturated fatty acid product.
21. The method of claim 20, wherein said substrate is dihomo-gamma-linolenic acid or arachidonic acid and said product polyunsaturated fatty acid is eicosatetraenoic acid or eicosapentaenoic acid, respectively, when said expressed desaturase is an omega-3-desaturase.
22. The method of claim 20, wherein said substrate polyunsaturated fatty acid is oleic acid and said product polyunsaturated fatty acid is linoleic acid, when said expressed desaturase is a delta 12-desaturase.
23. The method of claim 20, further comprising, after step (d), the step of:
(e) exposing said polyunsaturated fatty acid product of step (d) to one or more enzymes selected from the group consisting of a desaturase and an elongase, whereby the polyunsaturated fatty acid product of step (d) is catalytically converted into another polyunsaturated fatty acid product.
24. The method of claim 23, wherein said product polyunsaturated fatty acid is eicosatetraenoic acid or eicosapentaenoic acid and said another polyunsaturated fatty acid is eicosapentaenoic acid or omega 3-docosapentaenoic acid, respectively, when said expressed desaturase of step (d) is an omega 3-desaturase.
25. The method of claim 23, wherein said product polyunsaturated fatty acid is linoleic acid and said another polyunsaturated fatty acid is gamma-linolenic acid, when said expressed desaturase of step (d) is a delta 12-desaturase.
26. The method of claim 23 further comprising the step of exposing said another polyunsaturated fatty acid to one or more enzymes selected from the group consisting of a desaturase and an elongase in order to convert said another polyunsaturated fatty acid to a final polyunsaturated fatty acid.
27. The method of claim 26 wherein said final polyunsaturated fatty acid is selected from the group consisting of omega 3-docosapentaenoic acid and docosahexaenoic acid, when said expressed desaturase of step (d) is an omega 3-desaturase.
28. The method of claim 26 wherein said final polyunsaturated fatty acid is selected from the group consisting of dihomo-gamma-linolenic acid, arachidonic acid, adrenic acid, omega 6-docosapentaenoic acid, eicosatetraenoic acid, stearidonic acid, eicosapentaenoic acid, omega 3-docosapentaenoic acid and docosahexaenoic acid, when said expressed desaturase of step (d) is a delta 12-desaturase.
29. A method of producing a polyunsaturated fatty acid comprising exposing a fatty acid substrate to a polypeptide having at least 50% amino acid identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID
NO: 42, whereby said fatty acid substrate is catalytically converted into said polyunsaturated fatty acid.
30. The method of claim 29, wherein the fatty acid substrate is dihomo-gamma-linolenic acid or arachidonic acid and said product polyunsaturated fatty acid is eicosatetraenoic acid or eicosapentaenoic acid, respectively, when said polypeptide is an omega 3-desaturase.
31. The method of claim 29, wherein said fatty acid substrate is oleic acid and said polyunsaturated fatty acid is linoleic acid, when said polypeptide is a delta 12-desaturase.
32. A composition comprising at least one polyunsaturated fatty acid selected from the group consisting of said product polyunsaturated fatty acid produced according to the method of claim 20, said another polyunsaturated fatty acid produced according to the method of claim 23, and said final polyunsaturated fatty acid produced according to the method of claim 26.
33. The composition of claim 32, wherein said product polyunsaturated fatty acid is eicosatetraenoic acid or eicosapentaenoic acid, when said expressed desaturase of step (d) is an omega 3-desaturase.
34. The composition of claim 32, wherein said product polyunsaturated fatty acid is linoleic acid, when said expressed desaturase of step (d) is a delta 12-desaturase.
35. The composition of claim 32, wherein said another polyunsaturated fatty acid is eicosapentaenoic acid or omega 3-docosapentaenoic acid, respectively, when said expressed desaturase of step (d) is an omega 3-desaturase.
36. The composition of claim 32, wherein said another polyunsaturated fatty acid is gamma-linolenic acid, when said expressed desaturase of step (d) is a delta 12-desaturase.
37. The composition of claim 32, wherein said final polyunsaturated fatty acid is selected from the group consisting of omega 3-docosapentaenoic acid and docosahexaenoic acid, when said expressed desaturase of step (d) is an omega 3-desaturase.
38. The composition of claim 32, wherein said final polyunsaturated fatty acid is selected from the group consisting of dihomo-gamma-linolenic acid, arachidonic acid, adrenic acid, omega 6-docosapentaenoic acid, eicosatetraenoic acid, stearidonic acid, eicosapentaenoic acid, omega 3-docosapentaenoic acid and docosahexaenoic acid, when said expressed desaturase of step (d) is a delta 12-desaturase.
39. A method of preventing or treating a condition caused by insufficient intake of at least one polyunsaturated fatty acid comprising administering to said patient said composition of claim 32 in an amount sufficient to effect said prevention or treatment.
CA2474894A 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof Expired - Fee Related CA2474894C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2714295A CA2714295C (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/060,793 US7211656B2 (en) 2002-01-30 2002-01-30 Desaturase genes, enzymes encoded thereby, and uses thereof
US10/060,793 2002-01-30
PCT/US2003/001698 WO2003064596A2 (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2714295A Division CA2714295C (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof

Publications (2)

Publication Number Publication Date
CA2474894A1 true CA2474894A1 (en) 2003-08-07
CA2474894C CA2474894C (en) 2012-07-03

Family

ID=27658343

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2714295A Expired - Fee Related CA2714295C (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof
CA2474894A Expired - Fee Related CA2474894C (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2714295A Expired - Fee Related CA2714295C (en) 2002-01-30 2003-01-21 Desaturase genes, enzymes encoded thereby, and uses thereof

Country Status (11)

Country Link
US (3) US7211656B2 (en)
EP (1) EP1480993B2 (en)
JP (1) JP4780916B2 (en)
AT (1) ATE402944T1 (en)
CA (2) CA2714295C (en)
DE (1) DE60322515D1 (en)
DK (1) DK1480993T4 (en)
ES (1) ES2310652T5 (en)
MX (1) MXPA04007588A (en)
PT (1) PT1480993E (en)
WO (1) WO2003064596A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439654A1 (en) * 2001-03-12 2002-09-19 The General Hospital Corporation Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells
US20040172682A1 (en) * 2003-02-12 2004-09-02 Kinney Anthony J. Production of very long chain polyunsaturated fatty acids in oilseed plants
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7214491B2 (en) * 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7238482B2 (en) 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
US8313911B2 (en) * 2003-05-07 2012-11-20 E I Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
EP2166071B1 (en) 2003-08-01 2016-01-06 BASF Plant Science GmbH Method for producing polyunsaturated fatty acids in transgenic organisms
AU2004290052B2 (en) 2003-11-12 2008-12-04 Corteva Agriscience Llc Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
US7504259B2 (en) * 2003-11-12 2009-03-17 E. I. Du Pont De Nemours And Company Δ12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast
JP2007527711A (en) * 2004-02-04 2007-10-04 ザ・ジェネラル・ホスピタル・コーポレイション Compositions and methods for altering the content of polyunsaturated fatty acids in biological cells
ES2375363T3 (en) 2004-02-27 2012-02-29 Basf Plant Science Gmbh METHOD FOR THE PREPARATION OF OMEGA-3 FATTY ACIDS INSURED IN TRANSGENIC ORGANISMS.
US9458436B2 (en) 2004-02-27 2016-10-04 Basf Plant Science Gmbh Method for producing polyunsaturated fatty acids in transgenic plants
DK1756280T3 (en) 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
EP2357244A3 (en) 2004-04-22 2011-11-23 Commonwealth Scientific and Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells.
AU2005250074B2 (en) * 2004-06-04 2011-04-14 Fluxome Sciences A/S Metabolically engineered cells for the production of polyunsaturated fatty acids
JP4587451B2 (en) * 2004-08-20 2010-11-24 サントリーホールディングス株式会社 Polypeptide having ω3 fatty acid desaturation activity, polynucleotide encoding the polypeptide, and use thereof
US7588931B2 (en) 2004-11-04 2009-09-15 E. I. Du Pont De Nemours And Company High arachidonic acid producing strains of Yarrowia lipolytica
AR059376A1 (en) 2006-02-21 2008-03-26 Basf Plant Science Gmbh PROCEDURE FOR THE PRODUCTION OF POLYINSATURATED FATTY ACIDS
US7943823B2 (en) 2006-04-28 2011-05-17 E.I. Du Pont De Nemours And Company Delta-8 desaturase and its use in making polyunsaturated fatty acids
EP2013335A2 (en) * 2006-05-01 2009-01-14 E.I. Du Pont De Nemours And Company Fungal delta12 desaturase and delta15 desaturase motifs
US7678560B2 (en) * 2006-05-17 2010-03-16 E.I. Du Pont De Nemours And Company Δ 5 desaturase and its use in making polyunsaturated fatty acids
US7695950B2 (en) * 2006-05-17 2010-04-13 E. I. Du Pont De Nemours And Company Δ5 desaturase and its use in making polyunsaturated fatty acids
AU2013202498B2 (en) * 2006-08-24 2015-04-30 Basf Plant Science Gmbh Isolation and characterization of a novel Pythium omega 3 desaturase with specificity to all omega 6 fatty acids longer than 18 carbon chains
AU2007291937B2 (en) 2006-08-29 2014-05-15 Commonwealth Scientific And Industrial Research Organisation Synthesis of fatty acids
UA102063C2 (en) * 2007-02-12 2013-06-10 Е. І. Дю Пон Де Немур Енд Компані Soyabean plant producing arachidonic acid
US7943365B2 (en) 2007-05-03 2011-05-17 E.I. Du Pont De Nemours And Company Δ-5 desaturases and their use in making polyunsaturated fatty acids
DE102007058991A1 (en) 2007-12-07 2009-06-25 Bayer Materialscience Ag The use of low-chloride, low-carbonate silica sand as retention material for solid acid catalysts, especially in solid-bed reactors for condensation reactions, preferably for production of Bisphenol A
IT1390848B1 (en) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L PHARMACEUTICAL COMPOUNDS
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
CN102317459A (en) 2008-11-18 2012-01-11 联邦科学技术研究组织 Enzymes and methods for producing omega-3 fatty acids
CN107630017A (en) 2011-03-07 2018-01-26 Dsm营养产品股份公司 It is engineered thraustochytriale microorganism belonging to genus
CA3148246A1 (en) 2012-04-12 2013-10-17 Rothamsted Research Ltd Production of omega-3 long chain polyunsaturated fatty acids
SG10201810439SA (en) 2012-06-15 2018-12-28 Commw Scient Ind Res Org Production of long chain polyunsaturated fatty acids in plant cells
GB201217524D0 (en) 2012-10-01 2012-11-14 Rothamsted Res Ltd Recombinant organisms
CN105189740B (en) 2013-03-13 2019-01-15 帝斯曼营养品股份公司 Engineered microorganisms
CN105683368A (en) 2013-08-27 2016-06-15 国立大学法人京都大学 Omega 3 unsaturated fatty acid enzyme and method for producing eicosapentaenoic acid
KR102535223B1 (en) 2013-12-18 2023-05-30 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 Lipid comprising long chain polyunsaturated fatty acids
SG11201610596PA (en) 2014-06-27 2017-01-27 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid
WO2016104607A1 (en) 2014-12-25 2016-06-30 国立大学法人京都大学 Novel ω3 fatty-acid desaturase and method for producing eicosapentaenoic acid

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (en) 1980-09-24 1982-08-24 Cetus Corp DIAGNOSTIC PROCESS AND PROBE
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5004863B2 (en) 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
US5416011A (en) 1988-07-22 1995-05-16 Monsanto Company Method for soybean transformation and regeneration
CA1338683C (en) 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5106739A (en) 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5175095A (en) 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
ATE110778T1 (en) 1990-05-25 1994-09-15 Du Pont NUCLEOTIDE SEQUENCE OF THE GENE FOR SOYA STEAROYL-ACP DESATURASE.
DE69033623T2 (en) * 1990-10-22 2001-05-23 Aicello Chemical Co ENGRAVING PROCESS WITH IMAGE MASK AND LIGHT-SENSITIVE LAMINATE FILM FOR THIS IMAGE MASK
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5518908A (en) 1991-09-23 1996-05-21 Monsanto Company Method of controlling insects
US5614393A (en) * 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
US5952544A (en) 1991-12-04 1999-09-14 E. I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5912120A (en) 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
CA2149223C (en) 1992-11-17 2007-04-24 Jonathan Edward Lightner Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants
ATE193729T1 (en) 1993-02-26 2000-06-15 Calgene Llc GEMINIVIRUS-BASED GENE EXPRESSION SYSTEM
DE4339010C2 (en) * 1993-06-25 2000-05-18 Pt Sub Inc Photohardenable product for printing plates
JPH09509848A (en) 1994-03-09 1997-10-07 アボツト・ラボラトリーズ Transgenic animals producing oligosaccharides and glycoconjugates
CA2184687A1 (en) 1994-03-09 1995-09-14 Pedro Antonio Prieto Humanized milk
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
US5922506A (en) * 1994-10-20 1999-07-13 Agfa-Gevaert, N.V. Imaging element comprising a hydrophobic photopolymerizable composition and method for producing lithographic plates therewith
US5654402A (en) 1994-10-26 1997-08-05 Michigan State University Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
US5631152A (en) 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
US5677108A (en) * 1995-04-28 1997-10-14 Polaroid Corporation On-press removable quenching overcoat for lithographic plates
US6143470A (en) * 1995-06-23 2000-11-07 Nguyen; My T. Digital laser imagable lithographic printing plates
US5820932A (en) * 1995-11-30 1998-10-13 Sun Chemical Corporation Process for the production of lithographic printing plates
US6140005A (en) * 1996-04-23 2000-10-31 Agfa-Gevaert, N.V. Imaging element and a method for producing a lithographic plate therewith
JP3995290B2 (en) 1996-08-23 2007-10-24 サントリー株式会社 Method for producing omega-9 polyunsaturated fatty acid and lipid containing the same
US6106992A (en) * 1996-11-14 2000-08-22 Dai Nippon Printing Co., Ltd. Photoresist film and process for producing back plate of plasma display panel
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
CA2285939C (en) † 1997-04-11 2010-06-15 Calgene Llc Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
US5968809A (en) † 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US7008664B1 (en) * 1998-06-11 2006-03-07 E. I. Du Pont De Nemours And Company Method for improving the carcass quality of an animal
US6403349B1 (en) * 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
DE19941609A1 (en) * 1999-09-01 2001-03-08 Inst Pflanzenbiochemie Ipb Fatty acid desaturase gene from plants
JP2001169731A (en) * 1999-12-17 2001-06-26 Showa Denko Kk Lipid metabolism improving agent for animal
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
US6849383B2 (en) * 2000-07-26 2005-02-01 Toyo Boseki Kabushiki Kaisha Photosensitive resin laminate, and signboard plate and signboard made of the laminate
TWI377253B (en) † 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms

Also Published As

Publication number Publication date
WO2003064596A3 (en) 2003-12-04
DK1480993T4 (en) 2012-08-13
MXPA04007588A (en) 2004-12-06
CA2474894C (en) 2012-07-03
CA2714295A1 (en) 2003-08-07
US7211656B2 (en) 2007-05-01
EP1480993A4 (en) 2006-03-08
JP2005515776A (en) 2005-06-02
US7723503B2 (en) 2010-05-25
DE60322515D1 (en) 2008-09-11
US8067674B2 (en) 2011-11-29
CA2714295C (en) 2013-05-28
WO2003064596A2 (en) 2003-08-07
ES2310652T5 (en) 2012-07-02
ES2310652T3 (en) 2009-01-16
ATE402944T1 (en) 2008-08-15
US20030196217A1 (en) 2003-10-16
DK1480993T3 (en) 2008-11-24
US20090226987A1 (en) 2009-09-10
EP1480993B1 (en) 2008-07-30
US20070124837A1 (en) 2007-05-31
PT1480993E (en) 2008-11-06
EP1480993A2 (en) 2004-12-01
JP4780916B2 (en) 2011-09-28
EP1480993B2 (en) 2012-05-16
WO2003064596A8 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
CA2474894A1 (en) Desaturase genes, enzymes encoded thereby, and uses thereof
CA2446439A1 (en) .delta.4-desaturase genes and uses thereof
CA2417484A1 (en) Elongase genes and uses thereof
CA2435685A1 (en) Desaturase genes and uses thereof
JP2004521608A5 (en)
US10633678B2 (en) Preparation of microbial oil
CA2341336A1 (en) Elongase genes and uses thereof
US7977469B2 (en) Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
EP1513941B1 (en) Preparation of microbial oil containing polyunsaturated fatty acids
CA2487095A1 (en) Elongase genes and uses thereof
WO2005047480A3 (en) Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
US8003853B2 (en) Fatty acid desaturases and uses thereof
FR2870258A1 (en) Producing new fatty acids from oil-producing yeast, useful in human or animal nutrition, medicine and cosmetics, comprises culturing yeast transformed with desaturases
US20100120103A1 (en) Recombinant Production Docosahexaenoic Acid (DHA) in Yeast
JP2009534032A5 (en)
EP0978563B1 (en) Delta 9-desaturase gene
AU1774899A (en) Desaturase
RU2011114558A (en) Δ-8-DESATURASE GENES, ENZYMES, CODED BY THEM, AND THEIR APPLICATION
KR101549147B1 (en) Recombinant vector for polyunsaturated fatty acids biosynthesis and yeast transformed by the same
CN102399758B (en) Mutant gene mRnD6D having delta <6> fatty acid dehydrogenase functions and use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170123